Edwards Lifesciences Trading Volume Drops 45.59% to $4.78 Billion Despite Strong Q1 Sales and Stock Gains

On April 25, 2025, Edwards Lifesciences (EW) closed at $4.78 billion in trading volume, marking a 45.59% decrease from the previous day. The stock price rose by 1.21%, marking the second consecutive day of gains, with a total increase of 7.92% over the past two days.

Edwards Lifesciences reported strong first-quarter sales, with total revenue reaching $1.41 billion, a 6.2% increase year over year. The company's transcatheter aortic valve replacements (TAVR) sales, its largest business segment, generated $1.05 billion, a 3.8% increase year over year. Additionally, transcatheter mitral and tricuspid therapies (TMTT) sales surged by 58.1% to $115 million.

Despite capacity constraints and increased costs due to tariffs and acquisitions, Edwards maintained its full-year financial forecasts. The company expects sales growth of 8% to 10% and adjusted earnings per share in the range of $2.40 to $2.50. Edwards anticipates new indications for its technologies, which will expand the pool of patients eligible for treatment, and is awaiting FDA approval for an expanded indication for its Sapien TAVR device in asymptomatic severe aortic stenosis patients.

Edwards' CFO, Scott Ullem, noted that the company has plans in place to mitigate the impact of tariffs and the weakening dollar. The company operates several manufacturing facilities in key business regions, with most of its production based in the U.S. However, Edwards may face a more significant impact from tariffs in 2026.